<DOC>
	<DOC>NCT01278095</DOC>
	<brief_summary>The purpose of the study is to compare the pharmacokinetics of a solid capsule formulation of GLPG0555 with a nanosuspension, and to assess safety and tolerability of a single dose of GLPG0555.</brief_summary>
	<brief_title>Oral Bioavailability of GLPG0555 in Different Solid Formulations</brief_title>
	<detailed_description />
	<criteria>healthy male BMI between 1830 kg/mÂ², inclusive. significantly abnormal platelet function or coagulopathy smoking drug or alcohol abuse</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>